Nitric Oxide–Based Topical Dermatology Therapeutics Market By Mechanism of Nitric Oxide Delivery (Polymer-Based NO-Releasing Therapies, Microbiome-Based NO-Generating Biologics, Emerging NO Delivery Technologies); By Indication (Viral Dermatology [Molluscum Contagiosum, Warts], Inflammatory Dermatology [Atopic Dermatitis, Acne, Rosacea], Anti-Infective Dermatology); By Modality (Topical Drugs, Live Biotherapeutics, Combination Platforms); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation and Forecast, 2026–2032

Nitric Oxide-Based Topical Dermatology Therapeutics Market: ZELSUVMI Launch Establishes the First Commercial Revenue Base

The Global Nitric Oxide-Based Topical Dermatology Therapeutics Market was valued at USD 16.2 million in 2025 and is projected to reach USD 195 million by 2032, growing at a CAGR of 42.7%, according to Strategic Market Research.

 

The market entered its first measurable commercial year in July 2025 with the U.S. launch of ZELSUVMI, or berdazimer topical gel 10.3%. Before that launch, topical nitric oxide was principally a clinical-development platform spanning viral, bacterial, fungal, and inflammatory skin conditions. ZELSUVMI generated USD 16.2 million in net product revenue during approximately six months of 2025, providing a direct revenue base for the market rather than requiring an estimate built from disease prevalence or theoretical treatment eligibility. Pelthos Therapeutics reported 8,948 dispensed units written by 2,712 unique prescribers during 2025. Quarterly volume increased from 2,716 units in the third quarter to 6,232 units in the fourth quarter, representing 129% sequential growth.

 

The 42.7% forecast CAGR reflects the unusually small partial-launch base in 2025. It should not be interpreted as a constant annual growth rate for the underlying treated population. Growth is expected to be concentrated in the first three to four commercial years as ZELSUVMI reaches more pediatric and dermatology practices, secures additional formulary coverage, converts prescriptions into paid claims, and potentially enters selected international markets. The USD 195 million base-case forecast does not assume that all historical nitric oxide programmes reach approval. A risk-adjusted approach is necessary because ZELSUVMI remains the only approved and commercially launched prescription topical nitric oxide product identified within the defined market.

 

A 16.7 Million Disease Pool Narrows Sharply Before Reaching Paid Prescriptions

Pelthos estimates that molluscum contagiosum affects approximately 16.7 million people in the United States, with up to six million new incidents annually, most of them among children. The company’s 2025 annual filing presents the figures more conservatively as approximately 16 million prevalent cases and three million to six million annual cases. These are management and manufacturer estimates rather than counts from a national molluscum registry, so they should be used to describe the potential disease pool rather than the number of diagnosed, insured, or treated patients.

Published pediatric research reports a point-prevalence range of approximately 5.1%–11.5% and incidence of about 12–14 cases per 1,000 children per year, although the underlying studies vary considerably by country, age, climate, and study design. Pelthos has separately described a point-prevalence pool of approximately three million to six million U.S. children aged 0–16. Warmer climates, crowded households, shared swimming facilities, close physical contact, and higher pediatric exposure contribute to geographic variation, making it inappropriate to extrapolate a single U.S. prevalence rate directly across the global population.

A substantial portion of infections never enter the pharmaceutical pathway. Pelthos estimates that as many as 73% of affected children go untreated, while its cited natural-history evidence indicates that approximately 30% continue to have lesions after 18 months. Molluscum often resolves without intervention, but persistent lesions, repeated autoinoculation, household transmission, atopic dermatitis, itching, bleeding, sensitive-site involvement, and visible lesions increase the probability that parents will seek active treatment. The commercial population therefore consists primarily of diagnosed patients whose disease burden justifies treatment and whose prescription receives payer approval—not all 16.7 million affected individuals.

 

ZELSUVMI Converts Nitric Oxide Science into a Prescription Market

The FDA approved ZELSUVMI on January 5, 2024, for the topical treatment of molluscum contagiosum in adults and children aged one year and older. Pelthos launched the product commercially on July 10, 2025. ZELSUVMI is the first and only FDA-approved prescription molluscum therapy that patients, parents, or caregivers can administer at home rather than requiring application or treatment in a physician’s office. The product is dispensed as two tubes containing berdazimer gel and hydrogel. Equal quantities are mixed immediately before application and applied once daily to each lesion for up to 12 weeks.

ZELSUVMI is a nitric oxide-releasing agent, but the FDA label states that its precise mechanism of action in molluscum contagiosum is unknown. It should therefore not be described as a clinically proven “targeted antiviral” in the same manner as a virus-specific systemic drug. Its commercial differentiation comes from locally releasing nitric oxide through the NITRICIL platform, providing a prescription, non-destructive, caregiver-administered treatment option for a condition historically managed through observation, office procedures, and conventional topical products.

The pivotal B-SIMPLE4 trial enrolled 891 patients. Complete lesion clearance at week 12 occurred in 32.4% of patients treated with berdazimer, compared with 19.7% receiving vehicle. The 12.7-percentage-point absolute difference supported regulatory approval, while also showing that most patients did not reach complete clearance within the 12-week assessment period. The full clinical programme included 1,596 participants across three randomized, vehicle-controlled trials, of whom 1,575 were pediatric patients. This pediatric exposure supports clinician confidence, but real-world adoption still depends on caregiver willingness to mix and apply the product every day.

Local tolerability can affect persistence. Application-site pain, including burning or stinging, occurred in 18.7% of treated subjects, erythema in 11.7%, pruritus in 5.7%, exfoliation in 5.0%, and dermatitis in 4.9%. These rates have not prevented early commercial adoption, but they matter when families compare a 12-week daily regimen with observation or a shorter provider-administered intervention.

 

First-Quarter 2026 Results Confirm Continued Prescription Conversion

Pelthos reported USD 10.7 million in ZELSUVMI net product revenue during the first quarter of 2026, up approximately 17% from USD 9.1 million in the fourth quarter of 2025. Dispensed volume increased 25%, from 6,312 units to 7,884 units. Between the July 2025 launch and March 31, 2026, the product generated USD 26.9 million in cumulative net sales, with 16,774 units dispensed through 4,867 unique prescribers. April 2026 volume reached another 3,776 units, taking cumulative dispensing beyond 20,000 units.

The prescriber base broadened from 1,223 clinicians in the third quarter of 2025 to 2,377 in the fourth quarter and 3,228 in the first quarter of 2026. Pelthos expanded its field force from 50 territory managers at the end of 2025 to 64 by March 2026. Those territories cover approximately 53% of molluscum claims and target pediatricians, adult and pediatric dermatologists, nurse practitioners, and physician assistants. Adoption is no longer concentrated exclusively among clinical-trial investigators, although public data do not disclose repeat prescriptions per clinician, rejected claims, completed courses, or unique treated patients.

Dispensed units must not be presented as patient counts. One patient may require more than one carton because of lesion number, treatment duration, quantity limits, or replacement dispensing. Conversely, a dispensed carton does not establish adherence or completion of the 12-week course. Manufacturer-reported unit volume remains the strongest public demand indicator until independent prescription-claims data become available.

 

USD 2,008.50 List Pricing Makes Market Access the Main Commercial Constraint

ZELSUVMI’s 2026 wholesale acquisition cost is USD 2,008.50 per carton, with no generic listed in the Connecticut disclosure. WAC is the price before rebates, discounts, copay assistance, wholesaler fees, chargebacks, and government deductions, so it is not equivalent to the manufacturer’s net revenue or the patient’s out-of-pocket cost. The 8,948 units dispensed in 2025 would represent approximately USD 18.0 million at list price, compared with the USD 16.2 million in reported net product revenue. The difference illustrates the importance of gross-to-net deductions even during the initial launch period.

Pelthos reported that one contracting agreement produced approximately 70% combined commercial and Medicaid coverage. Its May 2026 investor presentation indicated that commercial, cash, and patient-assistance channels represented 71% of total prescriptions, managed and fee-for-service Medicaid represented 29%, and Medicare represented less than 1%, consistent with the product’s primarily pediatric demand profile. The same presentation showed approximately 99% commercial covered lives and 59% Medicaid covered lives by the first quarter of 2026, although covered lives do not indicate unrestricted access or actual paid-claim rates.

A separate PBM-related agreement applies to an organization managing prescription benefits for more than 20 million covered lives. Formulary updates began on December 1, 2025, but Pelthos did not disclose the PBM’s identity, preferred tier, patient cost sharing, rebate level, or prior-authorization approval rate. The agreement expands the potential reimbursable population without establishing that 20 million people have unrestricted access.

Some plans narrow reimbursement well below the FDA label. Centene’s May 2026 policy requires patients to have lesions in a sensitive area, atopic dermatitis, or a weakened immune system. It also requires lesions to remain unresolved for at least six months and cause bleeding, itching, pain, or other discomfort. Coverage is limited to one kit every 14 days for no more than 12 weeks, and reauthorization is not permitted. Such criteria concentrate paid demand among persistent or clinically burdensome infections rather than supporting treatment at diagnosis across the full eligible population.

 

Office Procedures and Cantharidin Capture Patients Before Nitric Oxide Therapy

The principal competitive threat is not another marketed nitric oxide gel. ZELSUVMI competes with watchful waiting, cantharidin, cryotherapy, curettage, topical retinoids, and other conventional or off-label treatments. Observation carries no pharmaceutical cost, while destructive procedures can provide immediate treatment during an office visit. Payer policies may require failure or intolerance of conventional treatment before authorizing ZELSUVMI, pushing the product into a later treatment position despite its broad FDA label.

YCANTH is the most commercially relevant branded substitute. It is an FDA-approved, provider-administered cantharidin treatment applied in a medical setting. Verrica Pharmaceuticals reported USD 15.3 million in U.S. YCANTH net product revenue and 51,296 dispensed applicators during 2025. These figures confirm that molluscum supports a monetized active-treatment market, but they also show that ZELSUVMI must compete against an established office-administered pharmaceutical rather than relying only on conversion from untreated disease.

ZELSUVMI’s advantage is shifting treatment from an office procedure to the home. Families may avoid procedure-associated pain, scheduling delays, travel, and repeated clinic visits. The trade-off is a daily two-component application process lasting as long as 12 weeks. Product adoption will be strongest where families value home administration and physicians believe the lesion burden warrants active treatment, but it will be weaker where spontaneous resolution remains acceptable or where a payer prefers a conventional intervention.

 

SB204, SB414, SB208, and SB207 Extend the Platform Beyond Molluscum

The NITRICIL platform has been clinically studied across acne vulgaris, atopic dermatitis, psoriasis, tinea pedis, onychomycosis, external genital and perianal warts, and molluscum contagiosum. More than 3,400 participants had received topical berdazimer formulations across the historical development programme by the time of the later molluscum trials. The platform seeks to exploit nitric oxide’s antiviral, antibacterial, antifungal, immunomodulatory, and antibiofilm activity through formulations designed to control local release.

SB204 for acne vulgaris has completed nine Phase 1 studies, three Phase 2 studies, two 12-week Phase 3 efficacy trials, and a 40-week safety study. One pivotal trial achieved all three co-primary endpoints, while the second achieved only one, preventing the programme from supporting an immediate regulatory filing. Pelthos’s disclosed development assumptions place a potential NDA approximately 4.5 years away if the programme is restarted, financed, and produces successful additional pivotal evidence. Acne offers a far larger potential prescription population than molluscum, but no SB204 revenue should be included in the present market size.

SB414 for atopic dermatitis and psoriasis has completed early clinical work and is described as a Phase 1/2-stage berdazimer topical cream programme. Pelthos’s May 2026 presentation estimated approximately 7.5 years to a possible NDA filing. This places SB414 in long-duration strategic optionality rather than the near-term commercial forecast.

SB208 for tinea pedis and onychomycosis is described as a Phase 2/3-stage low-alcohol berdazimer gel. Company planning assumptions indicate approximately five years to an NDA for tinea pedis and around 6.5 years where onychomycosis development or label expansion is included. Earlier clinical work found no major safety concern with once-daily administration in tinea pedis, but new trials, financing, regulatory alignment, and commercial partnerships would be required before the programme contributes revenue.

SB207 for external genital and perianal warts is described as a Phase 3-stage formulation using the same active berdazimer gel component as ZELSUVMI with a different hydrogel component. Pelthos has contractual development rights to SB207, while Ligand owns the principal rights to SB204, SB414, and SB208. Pelthos would need separate licences to develop or commercialize those other indications. This ownership structure makes licensing, API supply, royalties, and development partnerships central to the platform’s future value.

 

Diabetic Wounds Are an Adjacent Nitric Oxide Opportunity, Not Current Core Revenue

Nitric oxide-generating dressings, gels, footbaths, and delivery systems are being investigated for diabetic foot ulcers and chronic non-healing wounds. The scientific rationale includes antimicrobial and antibiofilm effects, vascular signalling, angiogenesis, and wound-repair activity. ClinicalTrials.gov records include nitric oxide footbath systems, wound dressings, plasma generators, and topical delivery technologies. Many are devices, combination products, or wound-care systems rather than prescription topical dermatology drugs. They should therefore be treated as an adjacent market unless the report’s scope is expanded to include wound-care devices and dressings.

Nitric oxide’s multiple antimicrobial targets may lower the likelihood that microorganisms develop resistance compared with single-target antibiotics. However, it is too absolute to state that nitric oxide “does not cause resistance.” Current evidence supports a potentially lower propensity for resistance and activity against biofilms, not a guarantee that resistance can never emerge.

 

U.S. Manufacturing Capacity Supports Expansion Without Immediate Major Capital Spending

Pelthos has produced more than one metric ton of NITRICIL active pharmaceutical ingredient at its U.S. facility, including registration, validation, and commercial batches. The API has a 36-month shelf life, and the company reports sufficient capacity for its existing ZELSUVMI forecast. Management estimates that theoretical API capacity could be roughly doubled through increased shifts and personnel without material near-term capital expenditure. Orion Corporation manufactures the finished commercial product under a multi-year supply arrangement.

Internal API manufacturing protects proprietary production methods and controls the longest-lead-time element of the supply chain. It also creates potential API and technology-transfer revenue if Ligand or future licensees advance SB204, SB414, SB208, or other NITRICIL programmes. Supply risk remains concentrated in specialized raw materials, hazardous-material transportation, and reliance on an external finished-product manufacturer.

 

International Revenue Remains Dependent on Licensing and Regulatory Execution

The United States is the only country currently supporting verified in-scope product revenue, prescription units, prescriber counts, payer policies, and list pricing. Japan represents a separate development route through Sato Pharmaceutical. A small Japanese Phase 2 study enrolled 20 pediatric patients and reported 60% complete clearance at week 12, but the open-label design and limited sample prevent direct comparison with the U.S. pivotal programme. Japanese development remains pre-commercial and should not be included as current market revenue.

Pelthos’s licence requires commercially reasonable efforts to establish a third-party commercialization agreement for France, Germany, Italy, Spain, and the United Kingdom by September 30, 2026. The agreement also identifies March 31, 2027, as a regulatory-approval milestone for those markets. These are contractual obligations rather than confirmed approval or launch dates. European revenue should be introduced gradually in the forecast and discounted for partnership, regulatory, pricing, and reimbursement risk.

 

Market Outlook

The nitric oxide-based topical dermatology therapeutics market will remain concentrated in ZELSUVMI and U.S. molluscum prescriptions through the near term. The strongest growth indicators are USD 26.9 million in cumulative net sales through March 2026, 16,774 dispensed units, 4,867 unique prescribers, a 25% quarterly volume increase, 64 commercial territories, and expanding commercial and Medicaid coverage. These metrics provide stronger evidence of market formation than multiplying prevalence by list price.

The USD 195 million forecast for 2032 assumes continuing U.S. prescription growth, improving payer conversion, moderate international contribution, and limited risk-adjusted pipeline revenue. The projection remains constrained by spontaneous disease resolution, an estimated untreated rate of up to 73%, a 32.4% pivotal-trial complete-clearance rate, USD 2,008.50 list pricing, prior authorization, step requirements, daily caregiver administration, and competition from YCANTH and destructive procedures.

ZELSUVMI has validated topical nitric oxide as a commercial drug platform, but the broader category will not become a diversified dermatology market until another NITRICIL indication or competing nitric oxide product progresses through pivotal development and regulatory approval. Until then, market value, growth, and competitive positioning will be determined primarily by one product’s ability to convert a large pediatric infection pool into reimbursed, completed prescription courses.

 

 

Nitric Oxidebased Topical Dermatology Therapeutics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 16.2 Million
Revenue Forecast in 2032	USD 195 Million
Overall Growth Rate	CAGR of 42.7% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Mechanism of Nitric Oxide Delivery	Polymer-Based NO-Releasing Therapies; Microbiome-Based NO-Generating Biologics; Emerging NO Delivery Technologies
By Indication	Viral Dermatology (Molluscum Contagiosum, Warts); Inflammatory Dermatology (Atopic Dermatitis, Acne, Rosacea); Anti-Infective Dermatology
By Modality	Topical Drugs; Live Biotherapeutics; Combination Platforms
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Market Drivers – Commercial Launch of Nitric Oxide-Based Therapies	FDA approval and commercialization of nitric oxide-based topical products are transforming the category from an experimental platform into a prescription dermatology market.
Market Drivers – Rising Demand for At-Home Dermatology Treatments	Patient preference for non-invasive, self-administered therapies is increasing demand for topical solutions that reduce dependence on repeated clinic-based procedures.
Market Drivers – Expansion of Specialty Dermatology Platforms	Growing investment in targeted dermatology therapies, microbiome-based approaches, and novel drug-delivery technologies is creating new opportunities for nitric oxide platforms.
Customization Option	Available upon request